Zymeworks Inc. (ZYME) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDT
Company Participants
Kenneth Galbraith – Chairman of the Board, CEO & President
Conference Call Participants
Frank Tang
Presentation
Frank Tang
All right. Hello, everyone. My name is Frank Tang, and I’m with the Investment Banking Division at Morgan Stanley. Thank you all for joining us for the Fireside Chat with Zymeworks. I’m joined here today with — by the Chairman and CEO, Ken Galbraith.
Question-and-Answer Session
Frank Tang
Ken, a lot has — welcome back, and a lot has evolved since last year, since we were here? It would be great if you could provide an update on where Zymeworks stands today and give us an overview of your broad model across licensed royalty assets, zani, the wholly owned TCEs, your ADC platform, and now the Theravance acquisition.
Kenneth Galbraith
Chairman of the Board, CEO & President
No, it’s a great thing. And again, great to be back here again this year with you, back to school, back to work. I think it’s a long week already, but I’m really happy to be here and have a chance to update you on Zymeworks. For 2026, we’ve had an amazing year already as a company, and it’s not finished yet. But obviously, with the recent FDA approval of zanidatamab in first-line GEA patients and HER2-overexpressing GEA patients, we’ve made this amazing journey from discovering this molecule inside our company 11 years ago.
With a great protein engineer came up with this idea of creating this bispecific antibody that would really create a brand new class of agent to be able to use in the HER2 class. And over the past 11 years, we’ve traveled that journey of trying to move that into clinical studies
